Which has better valuation and earnings, PRME or KRRO?

Korro Bio has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prime Medicine $4.63M 156.31 -$201.14M -$1.06 N/A Korro Bio $6.39M 23.42 -$117.26M -$10.00 N/A

Is PRME or KRRO more profitable?

Korro Bio has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Korro Bio's return on equity of -114.26% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Prime Medicine -4,613.11% -188.27% -59.11% Korro Bio N/A -114.26% -68.57%

Does the media prefer PRME or KRRO?

In the previous week, Korro Bio had 1 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for Korro Bio and 9 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat Korro Bio's score of 0.24 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Korro Bio 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALLO or KRRO more profitable?

Allogene Therapeutics' return on equity of -50.04% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -50.04% -36.74% Korro Bio N/A -114.26% -68.57%

Does the media prefer ALLO or KRRO?

In the previous week, Korro Bio had 6 more articles in the media than Allogene Therapeutics. MarketBeat recorded 10 mentions for Korro Bio and 4 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.72 beat Korro Bio's score of 0.24 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KRRO or CBIO more profitable?

Crescent Biopharma's return on equity of -101.50% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio N/A -114.26% -68.57% Crescent Biopharma N/A -101.50% -86.86%

Does the media favor KRRO or CBIO?

In the previous week, Crescent Biopharma had 2 more articles in the media than Korro Bio. MarketBeat recorded 12 mentions for Crescent Biopharma and 10 mentions for Korro Bio. Crescent Biopharma's average media sentiment score of 0.55 beat Korro Bio's score of 0.24 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is EPRX or KRRO more profitable?

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Korro Bio N/A -114.26% -68.57%

Does the media prefer EPRX or KRRO?

In the previous week, Korro Bio had 7 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 10 mentions for Korro Bio and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.88 beat Korro Bio's score of 0.24 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate YDES or KRRO?

Korro Bio has a consensus price target of $16.50, suggesting a potential upside of 62.40%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts plainly believe Korro Bio is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Korro Bio 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 2.92

Which has preferable valuation & earnings, YDES or KRRO?

YD Bio has higher earnings, but lower revenue than Korro Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Korro Bio $6.39M 23.42 -$117.26M -$10.00 N/A

Is YDES or KRRO more profitable?

YD Bio's return on equity of 0.00% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Korro Bio N/A -114.26% -68.57%

Does the media prefer YDES or KRRO?

In the previous week, Korro Bio had 7 more articles in the media than YD Bio. MarketBeat recorded 10 mentions for Korro Bio and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.27 beat Korro Bio's score of 0.24 indicating that YD Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Korro Bio 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Korro Bio (KRRO) Competitors

$10.16 -0.42 (-3.97%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.14 -0.02 (-0.15%)

As of 10/9/2026 05:09 PM Eastern

Compare

KRRO vs. PRME, ALLO, CBIO, EPRX, and YDES

Should you buy Korro Bio stock or one of its competitors? Korro Bio's main competitors and comparable companies include Prime Medicine (PRME), Allogene Therapeutics (ALLO), Crescent Biopharma (CBIO), Eupraxia Pharmaceuticals (EPRX), and YD Bio (YDES). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Korro Bio compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Korro Bio has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Korro Bio's return on equity of -114.26% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Korro Bio	N/A	-114.26%	-68.57%

Prime Medicine currently has a consensus price target of $7.47, indicating a potential upside of 87.27%. Korro Bio has a consensus price target of $16.50, indicating a potential upside of 62.40%. Given Prime Medicine's higher probable upside, research analysts clearly believe Prime Medicine is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Korro Bio has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	156.31	-$201.14M	-$1.06	N/A
Korro Bio	$6.39M	23.42	-$117.26M	-$10.00	N/A

Prime Medicine has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market. Comparatively, Korro Bio has a beta of 3.13, suggesting that its share price is 213% more volatile than the broader market.

In the previous week, Korro Bio had 1 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for Korro Bio and 9 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat Korro Bio's score of 0.24 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Korro Bio	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Korro Bio beats Prime Medicine on 9 of the 17 factors compared between the two stocks.

How does Korro Bio compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Allogene Therapeutics presently has a consensus price target of $8.30, suggesting a potential upside of 468.49%. Korro Bio has a consensus price target of $16.50, suggesting a potential upside of 62.40%. Given Allogene Therapeutics' higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Korro Bio has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	25,220.77	-$190.89M	-$0.67	N/A
Korro Bio	$6.39M	23.42	-$117.26M	-$10.00	N/A

Allogene Therapeutics' return on equity of -50.04% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Korro Bio	N/A	-114.26%	-68.57%

Allogene Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.13, suggesting that its share price is 213% more volatile than the broader market.

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Korro Bio had 6 more articles in the media than Allogene Therapeutics. MarketBeat recorded 10 mentions for Korro Bio and 4 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.72 beat Korro Bio's score of 0.24 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Allogene Therapeutics beats Korro Bio on 9 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Crescent Biopharma?

Korro Bio (NASDAQ:KRRO) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Korro Bio presently has a consensus target price of $16.50, indicating a potential upside of 62.40%. Crescent Biopharma has a consensus target price of $32.40, indicating a potential upside of 117.30%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Crescent Biopharma is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Crescent Biopharma had 2 more articles in the media than Korro Bio. MarketBeat recorded 12 mentions for Crescent Biopharma and 10 mentions for Korro Bio. Crescent Biopharma's average media sentiment score of 0.55 beat Korro Bio's score of 0.24 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Korro Bio has a beta of 3.13, suggesting that its share price is 213% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Korro Bio has higher earnings, but lower revenue than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	23.42	-$117.26M	-$10.00	N/A
Crescent Biopharma	$10.84M	51.08	-$153.94M	-$6.72	N/A

Crescent Biopharma's return on equity of -101.50% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	N/A	-114.26%	-68.57%
Crescent Biopharma	N/A	-101.50%	-86.86%

Summary

Crescent Biopharma beats Korro Bio on 10 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Korro Bio. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Korro Bio	$6.39M	23.42	-$117.26M	-$10.00	N/A

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Korro Bio	N/A	-114.26%	-68.57%

Eupraxia Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.13, meaning that its share price is 213% more volatile than the broader market.

In the previous week, Korro Bio had 7 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 10 mentions for Korro Bio and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.88 beat Korro Bio's score of 0.24 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eupraxia Pharmaceuticals currently has a consensus target price of $17.80, indicating a potential upside of 138.61%. Korro Bio has a consensus target price of $16.50, indicating a potential upside of 62.40%. Given Eupraxia Pharmaceuticals' higher probable upside, equities analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

13.2% of Korro Bio shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Korro Bio beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Korro Bio compare to YD Bio?

YD Bio (NASDAQ:YDES) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, Korro Bio had 7 more articles in the media than YD Bio. MarketBeat recorded 10 mentions for Korro Bio and 3 mentions for YD Bio. YD Bio's average media sentiment score of 0.27 beat Korro Bio's score of 0.24 indicating that YD Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Korro Bio	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

YD Bio has a beta of -1.55, indicating that its stock price is 255% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.13, indicating that its stock price is 213% more volatile than the broader market.

13.2% of Korro Bio shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

YD Bio has higher earnings, but lower revenue than Korro Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Korro Bio	$6.39M	23.42	-$117.26M	-$10.00	N/A

YD Bio's return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Korro Bio	N/A	-114.26%	-68.57%

Korro Bio has a consensus price target of $16.50, suggesting a potential upside of 62.40%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts plainly believe Korro Bio is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Summary

Korro Bio beats YD Bio on 9 of the 12 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRRO vs. The Competition

Export

Metric	Korro Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$149.62M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-1.02	13.55	274.99	26.14
Price / Sales	23.42	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	1.86	17.17	11.22	6.33
Net Income	-$117.26M	-$22.69M	$3.50B	$382.15M
7 Day Performance	5.39%	-1.34%	-0.89%	-1.40%
1 Month Performance	-22.21%	-8.45%	-4.42%	-3.47%
1 Year Performance	-76.36%	14.02%	7.03%	1.18%

Korro Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRRO Korro Bio	2.3433 of 5 stars	$10.16 -4.0%	$16.50 +62.4%	-78.3%	$149.62M	$6.39M	N/A	57	Analyst Forecast
PRME Prime Medicine	3.463 of 5 stars	$3.09 +7.3%	$7.47 +141.8%	-36.0%	$560.46M	$4.63M	N/A	146
ALLO Allogene Therapeutics	2.8177 of 5 stars	$1.62 -0.6%	$8.30 +412.3%	-3.3%	$559.69M	$20K	N/A	152	Analyst Downgrade
CBIO Crescent Biopharma	2.9294 of 5 stars	$14.76 +1.6%	$29.60 +100.5%	+21.5%	$548.19M	$10.84M	N/A	44	Analyst Upgrade High Trading Volume
EPRX Eupraxia Pharmaceuticals	3.0227 of 5 stars	$8.31 +1.2%	$17.80 +114.2%	+20.5%	$540.32M	N/A	N/A	49	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRRO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Korro Bio (KRRO) Competitors

KRRO vs. PRME, ALLO, CBIO, EPRX, and YDES

How does Korro Bio compare to Prime Medicine?

Summary

How does Korro Bio compare to Allogene Therapeutics?

Summary

How does Korro Bio compare to Crescent Biopharma?

Summary

How does Korro Bio compare to Eupraxia Pharmaceuticals?

Summary

How does Korro Bio compare to YD Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Korro Bio (KRRO) Competitors

KRRO vs. PRME, ALLO, CBIO, EPRX, and YDES

How does Korro Bio compare to Prime Medicine?

Do insiders and institutionals have more ownership in PRME or KRRO?

Is PRME or KRRO more profitable?

Do analysts recommend PRME or KRRO?

Which has better valuation and earnings, PRME or KRRO?

Which has more risk & volatility, PRME or KRRO?

Does the media prefer PRME or KRRO?

Summary

How does Korro Bio compare to Allogene Therapeutics?

Do analysts recommend ALLO or KRRO?

Which has preferable earnings and valuation, ALLO or KRRO?

Is ALLO or KRRO more profitable?

Which has more risk and volatility, ALLO or KRRO?

Do insiders & institutionals hold more shares of ALLO or KRRO?

Does the media prefer ALLO or KRRO?

Summary

How does Korro Bio compare to Crescent Biopharma?

Do analysts rate KRRO or CBIO?

Does the media favor KRRO or CBIO?

Do institutionals and insiders believe in KRRO or CBIO?

Which has more volatility & risk, KRRO or CBIO?

Which has better earnings and valuation, KRRO or CBIO?

Is KRRO or CBIO more profitable?

Summary

How does Korro Bio compare to Eupraxia Pharmaceuticals?

Which has better valuation & earnings, EPRX or KRRO?

Is EPRX or KRRO more profitable?

Which has more risk & volatility, EPRX or KRRO?

Does the media prefer EPRX or KRRO?

Do analysts rate EPRX or KRRO?

Do insiders & institutionals have more ownership in EPRX or KRRO?

Summary

How does Korro Bio compare to YD Bio?

Does the media prefer YDES or KRRO?

Which has more risk and volatility, YDES or KRRO?

Do insiders and institutionals hold more shares of YDES or KRRO?

Which has preferable valuation & earnings, YDES or KRRO?

Is YDES or KRRO more profitable?

Do analysts rate YDES or KRRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools